A landmark nephrology analysis reinforced that sodium‑glucose cotransporter‑2 (SGLT2) inhibitors deliver kidney and cardiovascular benefits across patients with differing glomerular filtration rates and albuminuria levels, including people without diabetes. The large dataset—presented at ASN Kidney Week and published in JAMA—supports broader routine use of SGLT2 inhibitors in CKD and heart‑failure populations. Complementary preclinical work showed sotagliflozin outperformed dapagliflozin in rat models of salt‑sensitive hypertension and renal damage, highlighting pharmacologic differences within the class and the need for head‑to‑head clinical comparisons to refine agent selection in specific patient subgroups.